Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding.
Location: United States, Massachusetts, Boston
Total raised: $45M
Founded date: 2014
Investors 2
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| - | Dolby Fami... | dolbyventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.02.2016 | Series A | $45M | - |
Mentions in press and media 8
| Date | Title | Description |
| 11.01.2022 | Yumanity Therapeutics, Inc. Receives $500,000 Research Grant from the Michael J. Fox Foundation for Parkinsons Research | Yumanity Therapeutics, Inc. was awarded a $500,000 research grant from The Michael J. Fox Foundation for Parkinsons Research to further investigate preclinical efficacy and biomarker development for YTX-7739, which is in clinical developme... |
| 11.11.2021 | Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson's Disease | BOSTON - Yumanity Therapeutics (Nasdaq: YMTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease. The Company reported that its lea... |
| 10.11.2021 | Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson's Disease; Company Plans to Advance Program to Phase 2 | YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson’s disease YTX-7739 found to be generally well tolerated, demonstrating favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles... |
| 10.02.2016 | Yumanity Therapeutics Raises $45M in Series A Funding | Yumanity Therapeutics, a Cambridge, Mass.-based developer of drugs for neurodegenerative diseases, raised $45m in Series A funding. The round was led by Fidelity Management & Research Company with participation from Redmile Group, Alexa... |
| 10.02.2016 | Yumanity Therapeutics Closes $45M Series A | CAMBRIDGE, MA, Company focused on transforming drug discovery for diseases caused by protein misfolding, today announced a $45 million Series A financing. >> Click here for more funding data on Yumanity Therapeutics >> To ex... |
| 10.02.2016 | Yumanity raises $45M Series A for yeast-based drug discovery platform | This funding should take Yumanity all the way through the preclinical period, bringing it just short of first-in-man trials. Coles said that it’s too early to wager when the company might be ready to hit clinical trials – it’s focusing firs... |
| 10.02.2016 | Yumanity Therapeutics Closes $45 Million Series A Financing | - |
| - | Yumanity raises $45M Series A for yeast-based drug discovery platform | Cambridge startup Yumanity Therapeutics just closed out an impressive $45 million Series A – meant to fuel its yeast-based drug discovery platform through preclinical development. The investor syndicate is an interesting blend of strategics... |